What is Zacks Small Cap's Forecast for RANI FY2025 Earnings?

Key Points

• Zacks Small Cap raised their FY2025 EPS estimate for Rani Therapeutics from ($0.49) to ($0.34), with the current consensus estimate at ($1.01) per share.
• Rani Therapeutics' stock has an average rating of "Moderate Buy" with a target price of $8.50 according to various analysts.
• The company's recent share performance shows a significant rising trend, with shares trading up 26.7% at $2.85 as of Wednesday.

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) - Zacks Small Cap upped their FY2025 EPS estimates for shares of Rani Therapeutics in a research note issued to investors on Monday, October 20th. Zacks Small Cap analyst J. Vandermosten now expects that the company will post earnings per share of ($0.34) for the year, up from their previous estimate of ($0.49). The consensus estimate for Rani Therapeutics' current full-year earnings is ($1.01) per share. Zacks Small Cap also issued estimates for Rani Therapeutics' Q4 2025 earnings at ($0.01) EPS, FY2026 earnings at ($0.20) EPS and FY2027 earnings at ($0.17) EPS.

Several other equities analysts also recently commented on RANI. Wall Street Zen raised shares of Rani Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Maxim Group increased their price objective on shares of Rani Therapeutics from $5.00 to $10.00 and gave the company a "buy" rating in a research note on Monday. Weiss Ratings reissued a "sell (e+)" rating on shares of Rani Therapeutics in a research note on Wednesday, October 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $11.00 price objective on shares of Rani Therapeutics in a research note on Tuesday. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Rani Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $8.50.

Rani Therapeutics Trading Up 26.7%

NASDAQ RANI opened at $2.85 on Wednesday. The firm has a market capitalization of $204.83 million, a price-to-earnings ratio of -3.13 and a beta of -0.02. The firm's 50 day simple moving average is $0.61 and its 200 day simple moving average is $0.67. Rani Therapeutics has a 1 year low of $0.39 and a 1 year high of $3.32.

Rani Therapeutics (NASDAQ:RANI - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01.

Hedge Funds Weigh In On Rani Therapeutics

Several large investors have recently modified their holdings of RANI. Kestra Private Wealth Services LLC raised its stake in shares of Rani Therapeutics by 16.3% during the first quarter. Kestra Private Wealth Services LLC now owns 139,156 shares of the company's stock valued at $175,000 after acquiring an additional 19,536 shares during the last quarter. King Luther Capital Management Corp raised its stake in shares of Rani Therapeutics by 75.8% during the first quarter. King Luther Capital Management Corp now owns 58,000 shares of the company's stock valued at $73,000 after acquiring an additional 25,000 shares during the last quarter. Well Done LLC bought a new position in shares of Rani Therapeutics during the second quarter valued at $27,000. Janney Montgomery Scott LLC raised its stake in shares of Rani Therapeutics by 102.9% during the second quarter. Janney Montgomery Scott LLC now owns 55,200 shares of the company's stock valued at $28,000 after acquiring an additional 28,000 shares during the last quarter. Finally, Armistice Capital LLC bought a new position in shares of Rani Therapeutics during the second quarter valued at $1,619,000. Institutional investors own 30.19% of the company's stock.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.